We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prototype CTC Collection Device Tested Successfully in Model

By LabMedica International staff writers
Posted on 08 Apr 2019
Print article
Image: The wearable CTC collection device measures roughly 2 x 2.75 x 1 inches (5.08 x 6.98 x 2.54 cm), with the cancer-cell-capturing chip mounted on top. The catheter connecting to the patient runs through the hole in the top left corner (Photo courtesy of Dr. Tae Hyun Kim).
Image: The wearable CTC collection device measures roughly 2 x 2.75 x 1 inches (5.08 x 6.98 x 2.54 cm), with the cancer-cell-capturing chip mounted on top. The catheter connecting to the patient runs through the hole in the top left corner (Photo courtesy of Dr. Tae Hyun Kim).
A novel, wearable device for continuous isolation of circulating tumor cells (CTCs) from a peripheral vein was tested successfully in a dog model of human cancer.

CTCs are now an established biomarker for prognosis in patients with various carcinomas. However, current CTC isolation technologies rely on small blood volumes from a single venipuncture limiting the number of captured CTCs. This produces statistical variability and inaccurate reflection of tumor cell heterogeneity.

To improve this situation, investigators at the University of Michigan (Ann Arbor, USA) and collaborators at Colorado State University (Fort Collins, USA) designed an in vivo indwelling intravascular CTC isolation device to continuously collect CTCs directly from a peripheral vein. The system would return the remaining blood products after CTC enrichment, permitting interrogation of larger blood volumes than could be obtained by classic phlebotomy over a prolonged period of time.

The investigators produced a prototype wearable device that utilized novel protocols for mixing blood with the clot-inhibiting drug heparin and that employed sterilization methods for killing bacteria without harming the cell-targeting antibodies on the chip. The chip itself incorporated the nanomaterial graphene oxide to create a dense matrix of antibody-tipped molecular chains, which enabled it to trap more than 80% of the cancer cells from the whole blood that flowed across it.

The investigators reported in the April 1, 2019, online edition of the journal Nature Communications that they had validated the system in canine models. Results demonstrated the capability for screening 1–2% of the animal's entire blood supply over a period of two hours. This approach yielded a substantial increase in CTC capture, compared with serial blood draws.

"Nobody wants to have a biopsy. If we could get enough cancer cells from the blood, we could use them to learn about the tumor biology and direct care for the patients. That is the excitement of why we are doing this," said senior author Dr. Daniel F. Hayes, professor of internal medicine at the University of Michigan. "This is the epitome of precision medicine, which is so exciting in the field of oncology right now."

Related Links:
University of Michigan
Colorado State University

New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
New
Gastrin-17 ELISA
Human Gastrin-17 CLIA Kit
New
Cryptosporidium Infection Test
Crypto (Card) Rapid Test

Print article

Channels

Immunology

view channel
Image: The blood test for fungal infections provides faster results and has a less invasive process (Photo courtesy of 123RF)

Blood Test for Fungal Infections Could End Invasive Tissue Biopsies

For individuals with weakened immune systems, common molds found in the environment—such as in the soil, on damp walls, or on forgotten fruits—can lead to severe infections deep within the body.... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: The plasma cell dataset was created to assist in the accurate diagnosis (Photo courtesy of Shutterstock)

Novel Dataset of Plasma Cells to Aid Diagnosis of Multiple Myeloma

Myeloma is a rare blood cancer that originates in plasma cells, a type of immune cell responsible for producing antibodies that help fight infections. The disease begins when an abnormal plasma cell starts... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.